D. Yang

发表

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)

W. Zhang, G. Folprecht, K. Danenberg, 2012, The Pharmacogenomics Journal.

The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women

R. Baumgartner, N. Joste, D. Yang, 2014, Cancer Causes & Control.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

H. Lenz, W. Zhang, S. Okazaki, 2016, The Pharmacogenomics Journal.

Time course of Keap1-Nrf2 pathway expression after experimental intracerebral haemorrhage: correlation with brain oedema and neurological deficit

W. Zhang, D. Yang, H. Shang, 2013, Free radical research.

Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases

T. Gruenberger, H. Lenz, W. Zhang, 2015, The Pharmacogenomics Journal.

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

A. Barzi, H. Lenz, W. Zhang, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

H. Lenz, V. Heinemann, W. Zhang, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.

S. Groshen, M. Shah, H. Lenz, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic variants associated with colorectal brain metastases susceptibility and survival

M. Preusser, H. Lenz, W. Zhang, 2015, The Pharmacogenomics Journal.

Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer

H. Lenz, W. Zhang, S. Okazaki, 2015, The Pharmacogenomics Journal.

A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P).

D. Gandara, A. El-Khoueiry, D. Yang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.

M. Shah, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

An optimal maneuver control method for the spacecraft with flexible appendages

D. Liu, D. Yang, W. Zhang, 1988 .

Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab.

H. Lenz, W. Zhang, D. Yang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX).

S. Groshen, H. Lenz, D. Yang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

H. Lenz, A. El-Khoueiry, W. Zhang, 2016, The Pharmacogenomics Journal.

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

M. Rugge, G. Fontanini, G. Fasola, 2015, British Journal of Cancer.

Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer

H. Lenz, W. Zhang, K. Danenberg, 2011, The Pharmacogenomics Journal.

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer

H. Lenz, W. Zhang, S. Okazaki, 2016, The Pharmacogenomics Journal.

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer

H. Lenz, A. El-Khoueiry, W. Zhang, 2012, The Pharmacogenomics Journal.

Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence

M. Shah, H. Lenz, W. Zhang, 2012, The Pharmacogenomics Journal.

Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis

H. Lenz, M. LaBonte, R. Ladner, 2012, British Journal of Cancer.

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

S. Groshen, H. Lenz, W. Zhang, 2004, British Journal of Cancer.

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen

H. Lenz, W. Zhang, A. Gerger, 2013, The Pharmacogenomics Journal.

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

M. Kahn, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

H. Lenz, W. Zhang, D. Yang, 2014, The Pharmacogenomics Journal.

Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.

S. Groshen, H. Lenz, W. Zhang, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy

H. Lenz, W. Renner, H. Samonigg, 2013, The Pharmacogenomics Journal.

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

H. Lenz, A. El-Khoueiry, W. Zhang, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer

H. Lenz, W. Zhang, A. Gerger, 2014, The Pharmacogenomics Journal.

HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts

Thomas D. Schmittgen, M. Ferracin, G. Calin, 2013, Cell Death and Differentiation.

Variations in Genes Involved in Dormancy Associated with Outcome in Patients with Resected Colorectal Liver Metastases Original Articles Annals of Oncology

T. Gruenberger, A. Barzi, H. Lenz, 2022 .

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients

H. Lenz, W. Zhang, S. Okazaki, 2017, The Pharmacogenomics Journal.

VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer.

H. Lenz, W. Zhang, K. Danenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV).

H. Lenz, A. El-Khoueiry, W. Zhang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

D. Gandara, H. Lenz, A. El-Khoueiry, 2012, Investigational New Drugs.

Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer.

C. Haiman, H. Lenz, A. El-Khoueiry, 2009, Journal of Clinical Oncology.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy

P. Laurent-Puig, H. Lenz, W. Zhang, 2013, The Pharmacogenomics Journal.

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

H. Lenz, W. Zhang, S. Scherer, 2014, The Pharmacogenomics Journal.

Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence

M. Kahn, H. Lenz, W. Zhang, 2013, The Pharmacogenomics Journal.

A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).

A. El-Khoueiry, D. Yang, H. Lenz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women

R. Baumgartner, N. Joste, D. Yang, 2014, Cancer Causes & Control.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

H. Lenz, V. Heinemann, W. Zhang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.

A. Barzi, H. Lenz, W. Zhang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144)

H. Lenz, H. Chang, R. Ladner, 2007 .

Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)

H. Lenz, H. Chang, D. Yang, 2007 .

Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)

H. Lenz, D. Yang, A. Sherrod, 2004 .

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

H. Lenz, V. Heinemann, W. Zhang, 2017 .

VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms predict tumor recurrence in stage II and III colon cancer

H. Lenz, H. Chang, D. Yang, 2007 .

Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599.

D. Carbone, H. Lenz, W. Zhang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).

S. Groshen, H. Lenz, D. Yang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL)

S. Groshen, H. Lenz, D. Yang, 2004 .

Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.

H. Lenz, A. El-Khoueiry, W. Zhang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy.

S. Groshen, H. Lenz, W. Zhang, 2004, Journal of Clinical Oncology.